Hydrocortisone Acetate

證據等級: L5

預測適應症: 10 個

Hydrocortisone Acetate: From Topical Anti-Inflammatory Treatment to Alopecia Areata

One-Sentence Summary

Hydrocortisone acetate is a topical glucocorticoid widely used for inflammatory and allergic dermatological conditions, belonging to the corticosteroid drug class. The TxGNN model predicts it may be effective for Alopecia Areata, with 1 completed Phase 3 clinical trial and 2 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Topical anti-inflammatory and allergic dermatological conditions (based on pharmacological class; no formal SAHPRA registration on record)
Predicted New Indication	Alopecia areata
TxGNN Prediction Score	99.94%
Evidence Level	L2 (1 completed Phase 3 RCT)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, hydrocortisone acetate is a glucocorticoid that binds to intracellular glucocorticoid receptors (GR), suppressing NF-κB transcriptional activity and downregulating key pro-inflammatory cytokines — including IL-2, IFN-γ, and TNF-α — while also promoting T-cell apoptosis. When administered topically or by intralesional injection, it delivers targeted anti-inflammatory effect while minimising systemic exposure.

Alopecia areata is a T-cell mediated autoimmune disease in which CD8+ cytotoxic T cells breach immune privilege at the hair follicle, triggering a sustained inflammatory cycle that arrests hair growth. Hydrocortisone acetate’s mechanism directly targets this pathology: suppressing T-cell activation and pro-inflammatory cytokine release interrupts the autoimmune cascade at the follicular level. Intralesional corticosteroid injection is recognised as a first-line approach for alopecia areata in adults, while topical corticosteroids are preferred in paediatric cases where injection is poorly tolerated.

The pharmacological rationale is therefore coherent and mechanistically strong (★★★★☆). Notably, the single completed Phase 3 RCT (NCT01453686) directly evaluated hydrocortisone 1% cream in children with alopecia areata, providing the highest grade of direct clinical evidence available for this specific compound in this indication — even if the mild potency used in that trial may not represent the optimal formulation strength.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01453686	Phase 3	Completed	41	Randomised controlled trial directly comparing clobetasol propionate 0.05% cream versus hydrocortisone 1% cream in children with alopecia areata. Addresses a recognised gap in high-quality evidence for topical steroid potency selection in paediatric alopecia areata. Limitations: small sample (n=41); hydrocortisone 1% is a low-potency formulation that may underperform stronger corticosteroids, though it offers a more favourable safety profile for paediatric use.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
4755919	1973	Case Series	Przeglad Dermatologiczny	Early interventional report on treatment of severe alopecia areata using intralesional subcutaneous injections of hydrocortisone acetate suspension. Provides historically significant early evidence specifically for this compound and route of administration, predating modern RCT methodology.
153470	1979	Review	MMW, Münchener Medizinische Wochenschrift	Narrative review of advances in topical dermatological therapy; discusses hydrocortisone acetate as a benchmark comparator for anti-inflammatory potency, relevant to understanding its relative efficacy within the corticosteroid class.

South Africa Market Information

Hydrocortisone acetate currently has no SAHPRA registrations in South Africa (total licences: 0) and is classified as not marketed. Clinicians considering use would need to explore a Section 21 unregistered medicine access application via SAHPRA, or evaluate whether registered hydrocortisone-containing products (e.g., hydrocortisone 1% cream registered under different formulations or combination products) could provide an equivalent clinical option within the existing formulary.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety platform.

As no key warnings, contraindications, or drug interaction data were retrievable for this specific formulation in this evidence pack, clinicians should apply standard precautions applicable to topical corticosteroids:

Avoid prolonged use over large surface areas or under occlusive dressings, particularly in children
Use with caution near the eyes (risk of raised intraocular pressure and cataract with prolonged periocular application)
Be aware that systemic absorption may be increased in infants and young children due to higher body surface area–to–weight ratio
Intralesional hydrocortisone acetate suspension carries a small risk of local skin atrophy at the injection site

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed Phase 3 RCT directly evaluated hydrocortisone cream in paediatric alopecia areata, and corticosteroid therapy — topical and intralesional — is well-recognised clinical practice for this autoimmune hair-loss condition; the mechanistic basis is pharmacologically sound. However, the product is not currently registered in South Africa, formal SAHPRA safety data for this specific formulation is absent from the evidence pack, and the trial’s small sample size (n=41) limits the strength of the efficacy conclusion.

To proceed, the following is needed:

SAHPRA PI review: Obtain and review the full Professional Information document for hydrocortisone acetate to establish formal contraindications, warnings, and drug interactions before any clinical application
MOA confirmation: Retrieve complete mechanism of action data from DrugBank (DB14539) to support formal mechanistic justification documentation
Formulation and route assessment: Clarify which formulations (topical cream, intralesional suspension) are available or can be accessed under Section 21, and match route to target patient population (adult vs paediatric)
Section 21 application: Initiate SAHPRA Section 21 unregistered medicine access if clinical use is intended prior to full registration
Confirmatory evidence: Seek additional RCT data or systematic review evidence to upgrade evidence level from L2 to L1; the existing literature is limited and dated (1973–1979)
Comparative effectiveness: Evaluate hydrocortisone acetate against currently registered topical corticosteroids available in South Africa (e.g., betamethasone valerate, clobetasol propionate) for alopecia areata to justify its specific clinical positioning

⚠️ Disclaimer: This report is intended for research and evaluation purposes only and does not constitute medical advice. Drug repurposing candidates require rigorous clinical validation before therapeutic application. All prescribing decisions must be made by qualified healthcare professionals in accordance with SAHPRA-approved indications and relevant South African clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.